Award & Investment Overview
Cascader, a medical technology spinout supported by UCL Ventures, has completed a seed funding round led by Topcon Healthcare to advance artificial intelligence technologies for ophthalmology and oculomics.
The amount of the seed round was not disclosed.
Cascader was formed through a partnership between Moorfields Eye Hospital NHS Foundation Trust, Topcon Healthcare, and UCL Ventures. The company brings together ophthalmology, medical imaging, artificial intelligence, and commercialization capabilities to translate more than a decade of academic and clinical research into products for real-world healthcare use.
The seed financing will support development of Cascader’s first products, expansion of its team, and continued translation of its AI technology into clinical applications. Its initial product focus will be macular diseases, including age-related macular degeneration.
From a university commercialization perspective, Cascader represents a structured translational pathway in which academic research, an NHS clinical environment, university venture support, and an established medical imaging company have been combined around company formation and product development.
Approach & Ecosystem Context
Cascader builds on research conducted by scientists and clinicians at the UCL Institute of Ophthalmology and Moorfields Eye Hospital.
That research includes work beginning more than a decade ago on AI-enabled ophthalmology and oculomics. In 2016, researchers collaborated with Google DeepMind on applying deep learning to optical coherence tomography imaging. Research published in Nature Medicine in 2018 demonstrated an AI system capable of making referral recommendations across more than 50 sight-threatening conditions at a level reported as comparable to leading experts, while providing clinicians with information about how recommendations were generated.
Cascader provides a commercialization vehicle for translating that research base into clinical products.
The pathway is notable because company formation itself brings together several components that university technologies frequently need to cross the commercialization gap. UCL Ventures contributes venture creation and commercialization capabilities. Moorfields provides specialist ophthalmology and clinical expertise. Topcon Healthcare brings medical imaging and industry capabilities and is now leading the company’s seed financing.
This model goes beyond licensing intellectual property into a standalone startup. It creates a venture around a coordinated academic, clinical, and corporate partnership, potentially providing earlier access to product-development expertise, clinical workflows, imaging infrastructure, and eventual routes to healthcare adoption.
The seed round marks the next de-risking stage. Cascader now needs to convert its research foundation into defined products that can be validated within clinical workflows and ultimately deployed across healthcare settings.
Innovation & Technology
Cascader is developing AI technologies that analyze eye imaging and related data to support diagnosis and management of ophthalmic disease.
Its initial focus is macular disease, including age-related macular degeneration, a major cause of irreversible sight loss. The company intends to develop tools that help clinicians identify disease earlier and support clinical decision-making across the eye care pathway.
The underlying approach draws on optical coherence tomography and AI. OCT produces detailed imaging of structures within the eye, creating datasets that can be analyzed using machine learning to identify patterns associated with disease.
Cascader also plans to expand into oculomics, an emerging field that uses information contained in eye images to generate insights about health beyond ophthalmology.
The company identifies cardiovascular and neurodegenerative diseases as potential areas where eye imaging combined with AI could contribute additional diagnostic information.
Commercially, this creates two related development pathways. The nearer-term opportunity is AI-enabled ophthalmology focused on defined eye diseases and clinical workflows. The broader opportunity is developing oculomics technologies that use the eye as a source of biomarkers and health information relevant to systemic disease.
Potential Market Uses and Applications
Potential Ophthalmology Applications
- Age-related macular degeneration detection and management
- Macular disease assessment
- OCT image analysis
- Eye disease diagnosis
- Clinical referral support
- Disease monitoring and management
Potential Digital Health Applications
- AI-assisted clinical decision support
- Automated analysis of ophthalmic imaging
- Clinical workflow support
- Earlier identification of patients requiring specialist care
- Imaging-based patient stratification
Potential Community Eye Care Applications
- Community optometry practices
- Eye screening programs
- Referral decision support
- Coordination between community and specialist eye care
Potential Hospital Applications
- Specialist ophthalmology clinics
- Moorfields and other eye-care environments
- Imaging workflow support
- Clinical prioritization and disease management
Potential Oculomics Applications
- Cardiovascular disease assessment
- Neurodegenerative disease assessment
- Imaging-derived health biomarkers
- Earlier identification of systemic disease
- AI-enabled population health screening
Related Topics
UCL Ventures, Cascader, UCL Institute of Ophthalmology, Moorfields Eye Hospital, Topcon Healthcare, university spinouts, ophthalmology AI, oculomics, optical coherence tomography, OCT imaging, age-related macular degeneration, medical imaging, digital health, clinical AI, healthcare commercialization, university commercialization, venture creation, translational research
About innovosource
innovosource tracks GAP programs, including proof-of-concept programs, startup accelerators, translational research initiatives, university venture funds, and commercialization ecosystems that help move university innovations from research to market.
Our coverage is informed by the Mind the GAP Initiative and the GAP COA consortium activity, providing practical insights into the evolving commercialization landscape.
Learn more:
